aby-029
Small moleculeexperimentalImaging agent
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT02901925)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Epidermal growth factor receptor erbB1BINDING AGENT
EGFR binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aby-029
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07279116 | Phase 1 | Feb 28, 2026 | Dartmouth University, National Cancer Institute (NCI) |
| NCT07063693 | Phase 1 | Oct 31, 2025 | Dartmouth University, National Cancer Institute (NCI) |
| NCT03282461 | Early Phase 1 (Phase 1) | Jan 25, 2018 | Dartmouth University |
| NCT03154411 | Early Phase 1 (Phase 1) | May 26, 2017 | Dartmouth University |
| NCT02901925 | Early Phase 1 (Phase 1) | Dec 1, 2016 | Dartmouth University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dartmouth University | Academic/Hospital | 5 | 5 | 1 | 2016 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1